On August 29th, Professor Li Yuhua, Professor Xie Xiaoling and Dr. Hu Yuxing, Director of Hematology Department of Zhujiang Hospital of Southern Medical University, Chairman of Hematology Branch of Guangdong Medical Doctor Association, Director of Guangdong Engineering Research Center of Precision Immune Cell Therapy Technology, visited Guangdong Junhou Biological Medicine Co., LTD. (hereinafter referred to as "Junhou Biological"), a wholly-owned subsidiary of Shenzhen Cell Valley. Professor Shi Yuanyuan, chairman of our company, Dr. Feng Yaru, Executive President and production director of Junhou Biology, and Zhang Xuefeng, Director of Quality Management, warmly received and exchanged views.

Director Li and his delegation visited the smart exhibition hall, production and quality testing laboratory of Junhou Biology. At the subsequent symposium, Chairman Shi Yuanyuan introduced in detail the development history of Junhou Biology, the core technical team and the recent development results of product pipelines. Chairman Shi Yuanyuan introduced that Junhou Bio and Shenzhen Cell Valley currently have A total of 7,000 square meters of B+A, C+A grade in line with international GMP standards of viral vectors and cell product production workshops, as well as P2 laboratories. Thanks to the opening of the Shenzhen-China Channel, the resource flow of the cell therapy industry in Zhongshan and Shenzhen is more convenient, and a complete industrial chain layout from viral vector research and development, cell product production to clinical application is gradually being built. At the same time, in the field of clinical treatment, Shenzhen Cell Valley has established a close cooperative relationship with a number of domestic hospitals. Among them, Professor Guo Zhi's team of Huazhong Union Medical College Shenzhen Hospital used Anti-BCMA CAR-T and Ant-CD19 CAR-T produced by Shenzhen Cell Valley to successfully treat patients with drug-resistant and refractory multiple myeloma and patients with advanced recurrent follicular lymphoma, respectively. These treatment cases have been published in the Cell journals JCR Multidisciplinary Region I Heliyon and International Immunopharmacology (Region 2 of the Chinese Academy of Sciences) SCI journals. The success of these clinical studies indicates that the one-stop full-process service from basic research to clinical transformation advocated by Shenzhen Cell Valley has been recognized by doctors.

Director Li Yuhua spoke highly of the progress of Junhou Biology and Shenzhen Cell Valley in the field of cell therapy, and introduced that the hematology Department of Zhujiang Hospital of Southern Medical University ranks among the forefront in Southern China in terms of chemotherapy, transplantation, targeted therapy and cell therapy for malignant hematologic diseases, and has established the Cell Immunotherapy Center of Zhujiang Hospital as early as 2009. The department is committed to the development of adoptive cell immunotherapy technology for malignant tumors, including "CAR T cell therapy"; Recently, relying on the excellent work foundation of the department in the early stage, it has been approved by the Guangdong Provincial Development and Reform Commission of precision immune cell therapy technology Guangdong Engineering Research Center project support.

The exchange aims to deepen the strategic partnership between the Hematology Department of Zhujiang Hospital of Southern Medical University and Shenzhen Cell Valley, and jointly commit to the research and development and application of cell therapy products and technologies through the integration of medical enterprises. The two sides expressed that they would take the opportunity of cooperation to establish the Guangdong Engineering Research Center, give full play to their respective advantages, and bring more treatment options and better treatment effects to patients through multi-channel and deep-level cooperation.